<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html>
<head>
	<meta http-equiv="content-type" content="text/html; charset=utf-8"/>
	<title></title>
	<meta name="generator" content="LibreOffice 6.0.6.2 (Linux)"/>
	<meta name="author" content="Abdelrahman Moustafa Alsaid Ibrahim Albanna"/>
	<meta name="created" content="2017-03-02T10:21:00"/>
	<meta name="changedby" content="Abdelrahman Moustafa"/>
	<meta name="changed" content="2018-11-14T15:52:00"/>
	<meta name="AppVersion" content="14.0000"/>
	<meta name="Company" content="MSA"/>
	<meta name="DocSecurity" content="0"/>
	<meta name="HyperlinksChanged" content="false"/>
	<meta name="LinksUpToDate" content="false"/>
	<meta name="ScaleCrop" content="false"/>
	<meta name="ShareDoc" content="false"/>
	<style type="text/css">
		@page { margin: 0.33in }
		p { margin-bottom: 0.1in; direction: ltr; line-height: 115%; text-align: left; orphans: 2; widows: 2 }
		a:link { color: #0563c1 }
	</style>
</head>
<body lang="en-US" link="#0563c1" dir="ltr" style="border: 3.00pt solid #000000; padding: 0.13in 0.63in">
<div title="header">
	<p style="margin-bottom: 0.46in; line-height: 100%">                
	   
	</p>
</div>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="6" style="font-size: 28pt">Histopathology
of SCC</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><u><b>Tissue
of origin</b></u></font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">-Squamous
cell carcinoma is a malignant epithelial tumor which originates in
epidermis. </font></font>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">-Tumor
cells destroy the basement membrane and form sheets or compact masses
which invade the subjacent connective tissue (dermis).</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">-
Tumor cells show signs of epithelial dysplasia.</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">-Tumor
cells may surround and destroy blood vessels, and may invade the
lumina of vein or lymphatics.</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">-
In well differentiated carcinomas, tumor cells are
pleomorphic/atypical, but resembling normal keratinocytes from
prickle layer (large, polygonal, with abundant eosinophilic (pink)
cytoplasm and central nucleus). Their disposal tends to be similar to
that of normal epidermis: immature/basal cells at the periphery,
becoming more mature to the centre of the tumor masses. Tumor cells
transform into keratinized squames and form round nodules with
concentric, laminated layers, called &quot;cell nests&quot; or
&quot;epithelial/keratinous pearls&quot;. The surrounding stroma is
reduced and contains inflammatory infiltrate (lymphocytes). </font></font>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">-Poorly
differentiated squamous carcinomas contain more pleomorphic cells and
no keratinization. (H&amp;E, ob. x10)</font></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><br/>
</font></font><img src="SSC%20Histopathology_html_9fd84b79de9c25f7.jpg" name="Picture 28" align="left" hspace="12" width="513" height="330" border="0"/>
<br/>
<br/>

</p>
<p align="center" style="margin-left: 0.25in; margin-bottom: 0.11in; line-height: 108%">
<font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Well-differentiated
lesions show prominent keratinization and may form “pearl-like”
structures where dermal nests of keratinocytes attempt to mature in a
layered fashion (40x). </font></font>
</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_ae230e8bb04eec96.jpg" name="Picture 29" align="bottom" vspace="1" width="435" height="324" border="0"/>
</p>
<p align="center" style="margin-left: 0.25in; margin-bottom: 0.11in; line-height: 108%">
<font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Moderately
differentiated lesions of SCCI show much less organization and
maturation with significantly less keratin formation (40x).</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font color="#333333"><font face="Helvetica, serif"><font size="2" style="font-size: 10pt">.</font></font></font><span style="display: inline-block; border: none; padding: 0in"><font face="Arial, serif"><font size="2" style="font-size: 10pt"><b><span style="background: #ffffff"><font color="#000000">
Grading</span></span></b></font></font></font></p>
<ul>
	<li/>
<p style="margin-bottom: 0in; line-height: 100%; background: #ffffff">
	<font color="#000000"><font face="Arial, serif"><font size="2" style="font-size: 10pt">Often
	graded somewhat subjectively based on degree of differentiation and
	keratinization: well, moderate, poorly differentiated</font></font></font></p>
	<li/>
<p style="margin-bottom: 0in; line-height: 100%; background: #ffffff">
	<span style="display: inline-block; border: none; padding: 0in"><font face="inherit, serif"><font size="2" style="font-size: 10pt"><b><font color="#000000">Well
	differentiated:</span></b></font></font></font><font color="#000000"><font face="Arial, serif"><font size="2" style="font-size: 10pt">&nbsp;abundant
	pink cytoplasm, mild to moderate atypia, well developed
	keratinization</font></font></font></p>
	<li/>
<p style="margin-bottom: 0in; line-height: 100%; background: #ffffff">
	<span style="display: inline-block; border: none; padding: 0in"><font face="inherit, serif"><font size="2" style="font-size: 10pt"><b><font color="#000000">Moderately
	differentiated:</span></b></font></font></font><font color="#000000"><font face="Arial, serif"><font size="2" style="font-size: 10pt">&nbsp;focal
	keratinization; features between well and poorly differentiated</font></font></font></p>
	<li/>
<p style="margin-bottom: 0in; line-height: 100%; background: #ffffff">
	<span style="display: inline-block; border: none; padding: 0in"><font face="inherit, serif"><font size="2" style="font-size: 10pt"><b><font color="#000000">Poorly
	differentiated:</span></b></font></font></font><font color="#000000"><font face="Arial, serif"><font size="2" style="font-size: 10pt">&nbsp;no
	/ minimal keratinization, high nuclear to cytoplasmic ratio, nuclei
	are markedly atypical or frankly anaplastic</font></font></font></p>
	<li/>
<p style="margin-bottom: 0in; line-height: 100%; background: #ffffff">
	<span style="display: inline-block; border: none; padding: 0in"><font face="inherit, serif"><font size="2" style="font-size: 10pt"><b><font color="#000000">Undifferentiated:</span></b></font></font></font><font color="#000000"><font face="Arial, serif"><font size="2" style="font-size: 10pt">&nbsp;tumors
	presumed to be SCC based on prior biopsy at same site, but no
	keratinization identified by light microscopy; immunohistochemistry
	is usually necessary to exclude melanoma or sarcoma</font></font></font></p>
</ul>
<p style="margin-top: 0.19in; margin-bottom: 0.19in; line-height: 100%">
<img src="SSC%20Histopathology_html_1cb9d8c3b3ef79f9.jpg" name="Picture 6" align="bottom" hspace="1" vspace="1" width="238" height="229" border="0"/>
<font color="#333333">
                           </font>
<img src="SSC%20Histopathology_html_65f3699b05775990.jpg" name="Picture 7" align="bottom" vspace="1" width="239" height="229" border="0"/>
</p>
<p align="center" style="margin-top: 0.19in; margin-bottom: 0.19in; line-height: 100%">
<font color="#333333"><font face="Times New Roman, serif"><font size="4" style="font-size: 16pt"><b>Well
differentiated SCC</b></font></font></font></p>
<p align="center" style="margin-top: 0.19in; margin-bottom: 0.19in; line-height: 100%">
<font color="#333333">    </font>
<img src="SSC%20Histopathology_html_8a743d0d1fb59824.jpg" name="Picture 8" align="bottom" hspace="1" width="233" height="222" border="0"/>

               
<img src="SSC%20Histopathology_html_d76e726c1904b5bb.jpg" name="Picture 13" align="bottom" vspace="1" width="243" height="223" border="0"/>
<font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">	</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">	Moderately
differentiated SCC</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_1befb4712a2c2e2d.jpg" name="Picture 17" align="bottom" hspace="1" width="225" height="231" border="0"/>
</p>
<p align="center" style="text-indent: 0.5in; margin-bottom: 0.11in; line-height: 108%">
<font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><br/>
Poorly
differentiated SCC</font></font></p>
<p align="center" style="text-indent: 0.5in; margin-bottom: 0.11in; line-height: 108%">
<br/>
<br/>

</p>
<p align="center" style="text-indent: 0.5in; margin-bottom: 0.11in; line-height: 108%">
<br/>
<br/>

</p>
<p align="center" style="text-indent: 0.5in; margin-bottom: 0.11in; line-height: 108%">
<br/>
<br/>

</p>
<p align="center" style="text-indent: 0.5in; margin-bottom: 0.11in; line-height: 108%">
<br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"> 
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><b>Tumor
Grading</b></font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><b>Histopathological
Grading Systems for Oral Squamous Cell Carcinoma:</b></font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><b>1.
BRODER’S SYSTEM (1927)</b></font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><b>2.
ANNEROTH ET AL (1987) </b></font></font>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><b>3.
BRYNE’S INVASIVE FRONT GRADING (1989, 1992)</b></font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><b>4.
JAKOBBSON ET AL (1973)</b></font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><b>5.
FISHER (1975)</b></font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><b>6.
LUND ET AL (1975)</b></font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><b>7.
WILLEN ET AL (1975)	</b></font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><b>8.
CRISSMAN ET AL (1980)</b></font></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><b>1.Broder’s
(1920) classification: </b></font></font>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Accordingly,
tumors were graded on the basis of degree of differentiation and
keratinization of tumor cells into </font></font>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Grade
I: Well differentiated tumors – 75-100% of cells are differentiated
</font></font>
</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_3660552a905cbe27.png" name="Picture 30" align="bottom" width="448" height="385" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Grade
II: Moderately differentiated tumors – 50- 75% of cells are
differentiated </font></font>
</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_8a743d0d1fb59824.jpg" name="Picture 34" align="bottom" vspace="1" width="309" height="295" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Grade
III: Poorly differentiated tumors – 25-50% of cells are
differentiated </font></font>
</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_2f9a0d183f1cf28c.png" name="Picture 36" align="bottom" vspace="1" width="437" height="333" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Grade
IV: Anaplastic tumor – 0-25% of cells are differentiated</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_3b01cf016452b491.jpg" name="Picture 37" align="bottom" vspace="1" width="592" height="401" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"> 
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_94dbc9b451918b51.png" name="Picture 11" align="bottom" hspace="1" width="422" height="420" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><b>2.
Anneroth’s et al (1987) multifactorial grading system:</b></font></font><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">
According to this system, three parameters reflecting tumor cell
features including keratinization, nuclear pleomorphism, and mitoses
were evaluated in the whole thickness of the tumor and each scored
from 1-4. Pattern of invasion, stage of invasion, and
lymphoplasmacytic infiltration representing tumor-host relationship
were graded in the most invasive margins and scored from 1-4. Then
the sum of scores were grouped as follows: 6-12 grade I, 13-18 grade
II, 19-24 grade III, and the results were compared in the
metastasizing and non-metastasizing groups. </font></font>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_3660552a905cbe27.png" name="Picture 38" align="bottom" hspace="1" vspace="1" width="269" height="233" border="0"/>

<img src="SSC%20Histopathology_html_588847e58df8628e.png" name="Picture 39" align="bottom" width="266" height="211" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_3907ed601781e76b.png" name="Picture 18" align="bottom" hspace="1" width="252" height="207" border="0"/>

<img src="SSC%20Histopathology_html_f06c84a5961a05b0.png" name="Picture 20" align="bottom" hspace="1" width="252" height="227" border="0"/>
<img src="SSC%20Histopathology_html_2301375256f4eaad.png" name="Picture 19" align="bottom" hspace="1" vspace="1" width="276" height="244" border="0"/>

<img src="SSC%20Histopathology_html_c1e6c3ecf2c5ee93.png" name="Picture 21" align="bottom" width="272" height="220" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_762d7f7ae26fb3ca.png" name="Picture 5" align="bottom" vspace="1" width="641" height="318" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><b>3.
Bryne’s et al (1992) deep invasive cell grading system:</b></font></font><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">
According to this system, number of mitosis and stage of invasion was
omitted from the Anneroth’s grading system, while the rest of the 4
parameters mentioned above were measured in the deepest invasive
margins, and not in the whole thickness of the tumor, and graded
similarly. The sum of scores were grouped as follows: 4-8 grade I,
9-12 grade II, 13-16 grade III, and the results were compared in the
metastasizing and non-metastasizing groups. In cases where opinion of
the two authors differed, the disagreement was resolved by consensus
after joint review using a multiheaded microscope, and reviewed by
the third author. The results of the three grading systems in each of
the two groups (metastatic and non-metastatic) were analyzed by
logistic regression.</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_ede86cc95e37bb4e.png" name="Picture 12" align="bottom" vspace="1" width="422" height="335" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">4.</font></font>
<font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">JAKOBBSON
ET AL. (1973):</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">This
system not only includes the morphologic parameters “structure”,
“tendency to keratinization”, “nuclear aberrations”, and
“number of mitosis”, but also an evaluation of tumor-host
relationship as estimated by parameters such as “mode,” “stage
of invasion”, “vascular invasion” and “degree of
lymphoplasmocytic infiltration”</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_f71f5c9059510e2.png" name="Picture 40" align="bottom" vspace="1" width="592" height="331" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">5.
FISHER (1975) </font></font>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">They
modified slightly, the grading system developed by Jakobsson et al.
and indicated the malignancy grade of biopsy tissue tended to be
lower than the grade of definitive section obtained from surgical
specimen.</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_97dcb231aa7fec80.png" name="Picture 41" align="bottom" vspace="1" width="592" height="157" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">6.
LUND et al (1975)</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">They
also modified, grading system of Jakobsson et al. by presenting a
more exact definition of each parameter and grade and by introducing
a histologic score, defined a total sum of points divided by the
number of parameters evaluated. They found a statistically
significant correlation between microscopic score and death rate as
well as the frequency of local recurrence and regional lymph node
metastases in a series of 438 patients with squamous cell carcinoma
of the tongue.</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_9f8f9f90b3352b35.png" name="Picture 42" align="bottom" width="592" height="300" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">7.
WILLEN et al (1975)</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">They
also used modified system of Jakobsson et al. They consisted of the
deletion of two morphological parameter “structure” and “vascular
invasion”. The results showed no definitive correlation between the
clinical stage and histologic grading of malignancy. In the group
with no metastases the neoplasm were highly differentiated and
mitotic rates were low, but nuclear polymorphism was sometime
prominent. In the group with metastases the neoplasm were less
differentiated and advanced nuclear aberrations with increase mitotic
rates.</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_96ba01cd839a0982.png" name="Picture 43" align="bottom" vspace="1" width="592" height="256" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">8.</font></font>
<font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">CRISSMAN
e</font></font> <font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">They
modified the criteria outlined by Jakobsson et al. in two steps. They
included a different point scale for vascular invasion and structure
and mode of invasion into a single parameter “pattern of invasion”.
The new parameter was considered to reflect the capacity of the tumor
cells cohesiveness to keep the tumor cell population together as well
as the association of the invading tumor cell and host stroma.
“Differentiated” cohesive neoplasm infiltrated with well
delineated pushing margins, whereas “less differentiated”
non-cohesive neoplasm infiltrated as small, irregular neoplastic cell
aggregates or single cells. This modified system applied on 73 oral
squamous cell carcinoma patients. This result shows only the
“frequency of mitosis.”t al (1980)</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><a name="_GoBack"></a>
<img src="SSC%20Histopathology_html_d689cc5fc2aaf5ec.png" name="Picture 44" align="bottom" vspace="1" width="592" height="320" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt"><b>CONCLUSION</b></font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">A
significant percentage of patients with early stages of SCC have a
poor prognosis despite the small size of the tumor. Hence TNM staging
system used in clinical practice does not provide information on the
biological characteristic and aggressive clinical behavior of oral
SCC. The first and most widely practiced grading system for oral SCC
was developed by AC Broder. Since then a multitude of multifactorial
grading systems have developed. Jacobsson and Anneroth grading
system, are still sometimes used and studied. However, the most
recent of these multifactorial grading systems developed by Bryne et
al (1992), which analyses four factors of the carcinoma in its
invasive front is most reproducible but less popularly used. We found
a significant positive trend between Bryne’s deep invasive cell
grading system with lymph node metastasis; while all the other
grading systems, especially the most popularly used Broder’s
classification failed to show any statistical significance to lymph
node metastasis. In conclusion, we believe that Bryne’s grading of
the invasive parts of oral SCC could be taken as a valuable
predictive factor in lymph node metastasis. The clinical value of
this system can be increased if larger pieces of biopsies are taken
from the tumor. Generally, in the oral cavity, there are no
contraindications for the removal of biopsies measuring 15´ 5´ 5 mm
from representative areas. In most cases, this would be sufficient
for invasive cell grading. There could be scope of further improving
the clinical value of this histological grading system by including
new immunohistochemical markers like expression of vascular
endothelial growth factor-C (VEGF-C) and Ki-67 that take into account
the biological behavior of the tumor.</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="6" style="font-size: 28pt"><u><b>Variants
of SCC</b></u></font></font></p>
<p align="justify" style="margin-left: 0.25in; margin-bottom: 0.11in; line-height: 108%">
<font color="#000000"><span style="background: #ffffff">Conventional
SCC and variants of OSCC frequently arise within the oral cavity.
Precise histopathological diagnosis can help the clinician to plan
accurate treatment, as the prognosis of each of them differs
considerably.</span></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="justify" style="margin-left: 0.25in; margin-bottom: 0.11in; line-height: 108%">
<font face="Baskerville Old Face, serif"><font size="6" style="font-size: 22pt"><b>1-Conventional
Squamous Cell Carcinoma</b></font></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_69e9c4b039b80017.jpg" name="Picture 9" align="bottom" vspace="1" width="525" height="394" border="0"/>
</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font color="#666666"><b><span style="background: #fffcf0">Conventional
oral squamous cell carcinoma-malignant epithelial islands showing
keratin pearl formation. (H&amp;E stain, ×100)</span></b></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="6" style="font-size: 22pt"><b>2-
Verrucous Carcinoma</b></font></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font color="#000000"><span style="background: #ffffff">VC
is a very well-differentiated SCC that does not metastasize and has
an excellent prognosis with 5-year survival rate of approximately
75%.</span></font><font color="#642a8f"><u><span style="background: #ffffff">
</span></u></font><font color="#000000"><span style="background: #ffffff">The
lesion has a possibility of metastasis only if it is left long enough
and allowed to become more invasive</span></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_78723c05b88184.jpg" name="Picture 10" align="bottom" width="495" height="370" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 100%; background: #fffcf0">
<font color="#666666"><font face="Times New Roman, serif">Verrucous
carcinoma-broad bulbous pushing rete ridges with parakeratotic
plugging (H&amp;E stain, ×100)</font></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="6" style="font-size: 22pt"><b>3-
Adenoid squamous cell carcinoma</b></font></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font color="#000000"><span style="background: #ffffff">AdSCC
 occurs in the oral cavity infrequently as they usually affect
sun-exposed areas with vermillion border of the lip being the most
commonly affected site. They have a relative poorer prognosis as
compared with conventional SCC.</span></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_5388d96721d8398c.jpg" name="Picture 22" align="bottom" hspace="1" width="494" height="370" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 100%; background: #fffcf0">
<font color="#666666"><font face="Times New Roman, serif">Adenoid
squamous cell carcinoma -pseudoglandular pattern with acantholytic
tumor cells. (H&amp;E stain, ×200)</font></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font color="#642a8f"><font face="Times New Roman, serif"><font size="3" style="font-size: 12pt"><u><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065435/figure/F4/" target="figure"><br/>
</a><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065435/figure/F3/" target="figure"><br/>
</a></u></font></font></font><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="6" style="font-size: 22pt"><b>4-
Spindle cell carcinoma</b></font></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font color="#000000"><span style="background: #ffffff">SCSC
 metastasizes to the regional lymph nodes in upto 25% cases, but
distant metastasis is less common (5-15%). The 5-year survival rate
varies between 65-95%</span></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_a4551437385fd29a.jpg" name="Picture 23" align="bottom" width="495" height="370" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 100%; background: #fffcf0">
<font color="#666666"><font face="Times New Roman, serif">Spindle
cell carcinoma-malignant epithelial cells showing
spindling/sarcomatoid appearance (H&amp;E stain, ×100)</font></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065435/figure/F5/" target="figure"><font color="#642a8f"><font face="Times New Roman, serif"><font size="3" style="font-size: 12pt"><u><br/>
</u></font></font></font></a><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="6" style="font-size: 22pt"><b>5-Adenosquamous
carcinoma</b></font></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font color="#000000"><span style="background: #ffffff">ASC</span></font><font color="#642a8f"><u><span style="background: #ffffff">
</span></u></font><font color="#000000"><span style="background: #ffffff">
has an aggressive behavior, poorer prognosis and a propensity for
locoregional and distant metastasis, especially to the lungs. Larynx
is most commonly affected (70%) followed by the oral cavity (30%). It
shows approximately 2-year survival rate of approximately 55%</span></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_2235133a523b0d0a.jpg" name="Picture 24" align="bottom" hspace="1" width="496" height="370" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 100%; background: #fffcf0">
<font color="#666666"><font face="Times New Roman, serif">Adenosquamous
carcinoma-biphasic tumor showing true glandular differentiation
(arrowhead) along with squamous differentiation (arrow) (H&amp;E
stain, ×100). Inset depicts alcian bluepositive mucin secretion
(×400)</font></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065435/figure/F6/" target="figure"><font color="#642a8f"><font face="Times New Roman, serif"><font size="3" style="font-size: 12pt"><u><br/>
</u></font></font></font></a><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="6" style="font-size: 22pt"><b>6-Basaloid
squamous cell carcinoma</b></font></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font color="#000000"><span style="background: #ffffff">BSCC
 is regarded as a high-grade tumor with an increased propensity for
distant metastasis. It requires aggressive multimodality treatment.
The 2-year survival rate is 40%.</span></font><font color="#642a8f"><u><span style="background: #ffffff">
B</span></u></font><font color="#000000"><span style="background: #ffffff">SCC
more frequently affects the larynx. It has a better prognosis when
compared with location and stage-matched conventional OSCC.</span></font></p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><img src="SSC%20Histopathology_html_464039fda29ea00e.jpg" name="Picture 25" align="bottom" hspace="1" vspace="1" width="496" height="369" border="0"/>
</p>
<p style="margin-bottom: 0.11in; line-height: 100%; background: #fffcf0">
<font color="#666666"><font face="Times New Roman, serif">Basaloid
squamous cell carcinoma biphasic tumor showing basaloid malignant
islands with peripheral palisading and comedonecrosis (arrow) (H&amp;E
stain, ×100). Inset depicts squamous differentiation with keratin
pearl formation (arrowhead) (H&amp;E stain, ×100)</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><br/>
<br/>

</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">The
International Classification of Diseases for Oncology (ICD-O) system
lists a number of morphological subtypes and variants of malignant
squamous cell neoplasms, including: </font></font>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Papillary
thyroid carcinoma </font></font>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Verrucous
squamous cell carcinoma </font></font>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Papillary
squamous cell carcinoma </font></font>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Squamous
cell carcinoma </font></font>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Large-cell
keratinizing squamous cell carcinoma </font></font>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Large-cell
nonkeratinizing squamous cell carcinoma </font></font>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Small-cell
keratinizing squamous cell carcinoma </font></font>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Spindle-cell
squamous cell carcinoma</font></font></p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Adenoid/pseudoglandular
squamous cell carcinoma </font></font>
</p>
<p style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Intraepidermal
squamous cell carcinoma </font></font>
</p>
<p align="center" style="margin-bottom: 0.11in; line-height: 108%"><font face="Baskerville Old Face, serif"><font size="5" style="font-size: 18pt">Lymphoepithelial
carcinoma</font></font></p>
<div title="footer">
	<p align="center" style="margin-top: 0.46in; margin-bottom: 0in; line-height: 100%">
	<sdfield type=PAGE subtype=RANDOM format=PAGE>8</sdfield></p>
	<p style="margin-bottom: 0in; line-height: 100%"><br/>

	</p>
</div>
</body>
</html>